Publications
54
Citations
1,281
Est. group size
—
Recurring co-author estimate
Active years
36
Publishing since 1990
Michael Kays studies how antibiotics behave in the body (pharmacokinetics) and how effectively they fight infection (pharmacodynamics), with a particular focus on how body weight, obesity, and critical illness affect proper antibiotic dosing. Much of the work models drug levels in hospitalized patients to help determine safer, more effective dosing strategies for antibiotics such as cefazolin, cefepime, cephalexin, meropenem, and doripenem.
Publication output has been low and irregular over the last decade, with several years of no recorded output followed by small upticks (about 0.8 papers per year on average in the last 5 years).
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Population pharmacokinetics and pharmacodynamics of cefazolin using total and unbound serum concentrations in patients with high body weight
International Journal of Antimicrobial Agents · 2023
- 2564. Population Pharmacokinetics and Pharmacodynamics of Cefepime in Hospitalized Obese and Non-Obese Patients
Open Forum Infectious Diseases · 2023
- 1092. Population Pharmacokinetics of Cephalexin in Non-Obese and Obese Hospitalized Patients with Infectious Diseases
Open Forum Infectious Diseases · 2021
- 1547. Modeling Pharmacokinetics and Pharmacodynamics of Meropenem Utilizing a Novel Infusion Method of Bolus to Prolonged Infusion
Open Forum Infectious Diseases · 2019
- 2553. Addressing Knowledge and Practice Gaps in HIV Management with Engaging Continuing Education
Open Forum Infectious Diseases · 2019
- Use of Monte Carlo Simulations to Determine Optimal Carbapenem Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy
The Journal of Clinical Pharmacology · 2016
- Population Pharmacokinetics and Pharmacodynamics of Meropenem in Nonobese, Obese, and Morbidly Obese Patients
The Journal of Clinical Pharmacology · 2016
- Population Pharmacokinetics and Pharmacodynamics of Doripenem in Obese, Hospitalized Patients
Annals of Pharmacotherapy · 2016
- Total and Unbound Cefazolin Pharmacokinetics and Pharmacodynamics in Non-Obese and Obese Patients
Open Forum Infectious Diseases · 2016
- Open Forum Infectious Diseases×5
- The Journal of Clinical Pharmacology×2
- International Journal of Antimicrobial Agents×1
- Infection Prevention in Practice×1
- Annals of Pharmacotherapy×1
- Kevin M. Sowinski
Medicine · Purdue University West Lafayette
- Sharon M. Erdman
Medicine · Purdue University West Lafayette
- Jeffrey Lutmer
Medicine · The Ohio State University
- Mohammad Yaseen Abbasi
Medicine · Indiana University
- Robyn McCain
Medicine · Purdue University West Lafayette
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 20, 2026.
Claim or correct this profile